MAD-ID 2021

PROGRAMMATIC LEARNING OBJECTIVES

As an attendee of MAD-ID 2021, you will be able to earn up to 16 Continuing Pharmacy (1.6 CEU) or Medical Education hours.

At the conclusion of this activity, you should be able to:

Depending on which four classroom/workshop sessions the participant attends, four of the following eight learning objectives should be achieved:

    1. List and justify those beta-lactam antibiotics for which dosing can be optimized based on pharmacodynamic indices
    2. State the causes, prevalence and consequences of burnout in ID healthcare professions and propose methods for prevention and mitigation.
    3. Describe the guidance for assembly and dissemination of antibiograms and how they may be used in formulary and therapeutic decision making in your practice.
    4. Outline challenges to implementing antimicrobial stewardship in various healthcare settings and propose two or more approaches to accessing stewardship expertise
    5. Describe methods and provide examples of the application of in vitro susceptibility and pharmacodynamic data to clinical practice with one or more examples relevant to your practice
    6. List and provide rationales for the initiation of antimicrobial stewardship in the outpatient environment at your practice site
    7. Discuss best practices and list EMR tools useful in implementing and monitoring stewardship initiatives and provide an example of how you would utilize one at your practice site
    8. Identify methods for the collection and reporting of antimicrobial use metrics in various care settings appropos to your institution

The following learning objectives relate to the remaining educational sessions:

    1. Outline the various pros and cons of employing combination therapy in the treatment of Staphylococcus aureus and Gram-negative infections and describe clinical scenarios in which it may be useful
    2. List newer or improved vaccines and explain why they represent advances and how to inform patients of their importance
    3. Explain nuances to antimicrobial stewardship in special populations and propose methods for their application in pediatric and cystic fibrosis patients
    4. Describe how recent changes in epidemiology and management of HIV have altered practices in your healthcare environment
    5. Describe the microbiology, epidemiology and relevant pathophysiology of Candida auris and non-tuberular mycobacterial infections and propose stewardship measures that may be helpful in them
    6. Describe at least two significant findings that were presesnted at one of the recent national or international infectious diseases meetings and explain how they might affect stewardship practices at your practice site of institution
    7. Describe and evaluate new options for management of HIV infection in light of current known epidemiology and known challenges in therapy
    8. Explain and justify the new recommendations for AUC/MIC dosing of vancomycin and propose a plan for implementation at your practice site.